Gilman Michael
Known title: DirectorCIK: 0001291144
Associated companies
Transaction History
| SRRK | ▼ Sell | Open Market | 1,346 | $72K | 7/1/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,155 | $63K | 7/1/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 43 | $2K | 7/1/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 6,839 | $0 | 6/4/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 630 | $18K | 5/29/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 2,745 | $82K | 5/29/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 7,632 | $0 | 5/22/2025 | View on chart |
| SRRK | ▼ Sell | Gift | 37,459 | — | 11/12/2024 | View on chart |
| SRRK | ▼ Sell | Gift | 37,459 | — | 11/12/2024 | View on chart |
| SRRK | ▲ Buy | Grant | 13,500 | $0 | 6/27/2024 | View on chart |
| SRRK | ▼ Sell | Gift | 37,459 | — | 7/8/2022 | View on chart |
| SRRK | ▼ Sell | Gift | 37,459 | — | 7/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.